Systematic Financial Management LP Increases Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Systematic Financial Management LP grew its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,521,065 shares of the medical instruments supplier's stock after acquiring an additional 110,719 shares during the quarter. Systematic Financial Management LP owned about 6.23% of AngioDynamics worth $23,093,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. SBI Securities Co. Ltd. purchased a new stake in AngioDynamics in the fourth quarter valued at approximately $28,000. R Squared Ltd acquired a new position in shares of AngioDynamics in the 4th quarter valued at $49,000. US Bancorp DE grew its stake in shares of AngioDynamics by 1,938.0% during the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock valued at $61,000 after buying an additional 6,376 shares during the period. Quinn Opportunity Partners LLC acquired a new stake in shares of AngioDynamics during the 4th quarter worth $92,000. Finally, ProShare Advisors LLC purchased a new position in shares of AngioDynamics in the 4th quarter worth $100,000. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Stock Performance

ANGO traded down $0.08 on Tuesday, reaching $9.51. 269,880 shares of the company's stock were exchanged, compared to its average volume of 554,299. AngioDynamics, Inc. has a twelve month low of $5.47 and a twelve month high of $13.50. The company's 50 day moving average is $9.45 and its 200-day moving average is $9.44. The company has a market cap of $386.17 million, a price-to-earnings ratio of -1.69 and a beta of 0.58.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.00 million during the quarter, compared to analyst estimates of $70.30 million. The business's revenue was down 4.3% compared to the same quarter last year. Sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $16.00 price target (up previously from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.